Lead company/partner	Compound	Indication	Comments
Phase III Suspended
Lundbeck Inc.	idalopirdine	mild to moderate Alzheimer’s disease	STARBEAM, STARLIGHT; well tolerated but lacked efficacy.
Phase III Results Published
Synergy Pharmaceuticals Inc.	Trulance (plecanatide)	chronic idiopathic constipation	In the American Journal of Gastroenterology, online Feb. 7, 2017.
Merck KGAA	cladribine	brain atrophy in multiple sclerosis	CLARITY post-hoc analysis in the Multiple Sclerosis Journal, online Jan. 31, 2017.
Allergan PLC/Gedeon Richter Ltd.	Vraylar (cariprazine)	schizophrenia	Negative symptoms. The Lancet online, Feb. 6, 2017.
Phase III Interim/Top-line Results
Bayer AG/Janssen R&D LLC	Xarelto (rivaroxaban)	prevention of major cardiac events	COMPASS; met primary endpoint ahead of time.
Acorda Therapeutics Inc.	CVT-301	Parkinson’s disease	SPAN-PD; met primary endpoint .
Biofrontera AG	Ameluz (BF-200 ALA) plus daylight phototherapy	actinic keratosis (additional indication)	Met primary endpoint on lesions clearance rate.
Phase III Initiated
Novo Nordisk AS/Emisphere Technologies Inc.	semaglutide, oral	type 2 diabetes	PIONEER; all 10 Phase IIIa trials now underway.
AstraZeneca PLC	durvalumab	first line in small cell lung cancer	CASPIAN; with tremelimumab and chemotherapy.
Kiadis Pharma Netherlands BV	ATIR101 (treated donor T-cells)	acute myelogenous leukemia	HATCY; a transatlantic study.
AbbVie Inc./Enanta Pharmaceuticals Inc.	glecaprevir plus pibrentasvir	hepatitis C	M16-126; in genotype 5 or 6 infected patients.
Sumitomo Dainippon Pharma Co. Ltd.	napabucasin	pancreatic cancer	CanStem111P; plus nab-paclitaxel and gemcitabine.
Seikagaku Corp.	SI-613	osteoarthritis	Injected directly into the joints.
Phase III Announced
Flexion Therapeutics Inc.	Zilretta (FX-006)	knee osteoarthritis	A formulation of triamcinolone acetonide.
Updated Phase II Results
Ablynx NV/AbbVie Inc.	vobarilizumab (anti-IL-6R Nanobody)	methotrexate treated rheumatoid arthritis	Positive impact on disease activity, and well tolerated.
Hybrigenics SA	inecalcitol	chronic myelogenous leukemia	Positive early results after imatinib therapy.
Phase II Interim/Top-line Results
GW Pharmaceuticals PLC	tetrahydrocannabinol and cannabidiol	temozolomide treated glioma	Improved survival rate and survival duration.
Bristol-Myers Squibb Co.	lirilumab monotherapy	acute myelogenous leukemia	EffiKIR; missed primary endpoint, combination studies continue.
Grupo Ferrer Internacional SA	lorediplon	insomnia	Significant insomnia improvement and well tolerated.
AstraZeneca PLC	Bydureon (exenatide) once weekly injection	type 2 diabetes	DURATION-7; blood levels controlled after 28 weeks; no new safety signals.
Tracon Pharmaceuticals Inc.	TRC105 (MAb targeting endoglin)	recurrent glioblastoma	TRC105 plus Avastin did not improve PFS or overall survival versus Avastin alone.
Aslan Pharmaceuticals Pte. Ltd.	varlitinib	metastatic breast cancer	Combined with capecitabine, showed tumor shrinkage in HER2-positive disease.
DexTech	OsteoDex (a poly bisphosphonate)	prostate cancer, skeletal metastases	Bone marker values trending towards normal.
Phase II Initiation
Boehringer Ingelheim GMBH	Gilotrif (afatinib) with Keytruda (pembrolizumab)	squamous lung cancer	In patients with locally advanced or metastatic disease.
Ovid Therapeutics Inc.	OV101 (gaboxadol)	Angelman syndrome	STARS; to restore tonic inhibition.
Jazz Pharmaceuticals PLC	JZP-110	excessive sleepiness	In Parkinson’s disease.
Revive Therapeutics Ltd.	REV-004 (bucillamine)	cystinuria	An inherited autosomal recessive disease.
AbbVie Inc./Galapagos NV	ABBV-2222	cystic fibrosis	In ivacaftor treated patients.
Aldeyra Therapeutics Inc.	ADX-102	allergic conjunctivitis	Binds and traps aldehydes.
Pharmazz Inc	PMZ-2010	hypovolemic shock	To take place in India.

Pipeline Watch: Xarelto, CVT-301 And Ameluz Phase III Readouts

More from Pipeline Watch

More from R&D